Last updated: May 28, 2024
Sponsor: Affiliated Hospital of Nantong University
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Nasopharyngeal Cancer
Carcinoma
Treatment
Tocilizumab Asprin
Placebo
Clinical Study ID
NCT06442709
2023-K015
Ages 20-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Clinical diagnosis of NPC with distant metastasis
Must be able to swallow tablets
Exclusion
Exclusion Criteria:
Liver disease
Blood disease
Long-term use of anticoagulants
Study Design
Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Tocilizumab Asprin
Phase:
Study Start date:
August 01, 2021
Estimated Completion Date:
July 01, 2024
Study Description
Connect with a study center
Bo You
Nantong, Jiangsu 226000
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.